Edwards Lifesciences Management
Management criteria checks 3/4
Edwards Lifesciences' CEO is Bernard Zovighian, appointed in May 2023, has a tenure of 1.58 years. total yearly compensation is $12.87M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 0.012% of the company’s shares, worth $5.35M. The average tenure of the management team and the board of directors is 5.3 years and 4.6 years respectively.
Key information
Bernard Zovighian
Chief executive officer
US$12.9m
Total compensation
| CEO salary percentage | 7.6% |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.01% |
| Management average tenure | 5.3yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
Edwards Lifesciences Corporation's (NYSE:EW) Price Is Out Of Tune With Earnings
Dec 23
Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Dec 09At US$71.27, Is Edwards Lifesciences Corporation (NYSE:EW) Worth Looking At Closely?
Nov 26Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$13m | US$973k | US$1b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$1b |
| Mar 31 2023 | n/a | n/a | US$1b |
| Dec 31 2022 | US$3m | US$642k | US$2b |
Compensation vs Market: Bernard's total compensation ($USD12.87M) is about average for companies of similar size in the US market ($USD12.86M).
Compensation vs Earnings: Bernard's compensation has increased by more than 20% in the past year.
CEO
Bernard Zovighian (56 yo)
1.6yrs
Tenure
US$12,869,020
Compensation
Mr. Bernard J. Zovighian serves as Chief Executive Officer and Director at Edwards Lifesciences Corp since May 11, 2023 and was its President at Edwards Lifesciences Corp since January 1, 2023 until May 11...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | US$12.87m | 0.012% $ 5.3m | |
| Corporate VP & CFO | 10.9yrs | US$5.95m | 0.046% $ 20.5m | |
| Corporate Vice President of Strategy & Corporate Development | 8.8yrs | US$4.29m | 0.035% $ 15.4m | |
| Corporate VP and Group President of TAVR & Surgical Structural Heart | 1.9yrs | US$5.40m | 0.030% $ 13.3m | |
| Principal Accounting Officer | less than a year | no data | 0.00030% $ 132.4k | |
| Corporate VP of Advanced Technology & Chief Scientific Officer | 5.8yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Corporate VP & General Counsel | 5.3yrs | no data | no data | |
| Corporate Vice President of Public Affairs | 11.5yrs | no data | no data | |
| Corporate Vice President of Human Resources | 12.3yrs | no data | no data | |
| Senior Vice President of Quality & Regulatory Compliance | 1.4yrs | no data | no data | |
| GM & Senior VP of Surgical Structural Heart | 1.3yrs | no data | 0.00012% $ 52.9k |
5.3yrs
Average Tenure
58yo
Average Age
Experienced Management: EW's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.6yrs | US$12.87m | 0.012% $ 5.3m | |
| Independent Director | 9.8yrs | US$335.06k | 0.012% $ 5.4m | |
| Independent Director | 4.4yrs | US$329.97k | 0.0013% $ 578.0k | |
| Independent Director | 8.8yrs | US$335.06k | 0.012% $ 5.3m | |
| Independent Director | 8.4yrs | US$356.42k | 0.0046% $ 2.0m | |
| Independent Chairman | 10.1yrs | US$347.97k | 0.012% $ 5.2m | |
| Independent Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Independent Director | 4.6yrs | US$334.97k | 0.0019% $ 825.1k |
4.6yrs
Average Tenure
64yo
Average Age
Experienced Board: EW's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 07:54 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Edwards Lifesciences Corporation is covered by 73 analysts. 33 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Francis Mainwaring | Atlantic Equities LLP |
| David Rescott | Baird |
| Ishan Majumdar | Baptista Research |